<DOC>
	<DOCNO>NCT01261156</DOCNO>
	<brief_summary>The purpose study evaluate effect diltiazem pharmacokinetics ( PK ) pharmacodynamics ( PD ) E5555 metabolites healthy subject .</brief_summary>
	<brief_title>A Study Evaluate Effects Diltiazem , Moderate CYP3A4/A5 Inhibitor , Pharmacokinetics Pharmacodynamics E5555 Its Metabolites Healthy Subjects</brief_title>
	<detailed_description>This open-label , 2-arm study evaluate effect diltiazem give conjunction E5555 PK diltiazem metabolite . This Phase 1 study 24 healthy male female subject conduct single site . The planned duration treatment subject approximately 15 day include 1 day Treatment Period 1 14 day Treatment Period 2 .</detailed_description>
	<mesh_term>Diltiazem</mesh_term>
	<criteria>Inclusion : Provide write informed consent Healthy , nonsmoking , male female subject age great equal 18 year 55 year Body mass index ( BMI ) great equal 18 less equal 32 kg/m2 Screening All female must negative serum beta human chorionic gonadotropin test result Screening Baseline . Females childbearing potential must agree use medically acceptable method contraception commence least one menstrual cycle prior start study drug , throughout entire study period 90 day study drug discontinuation . The subject exempt requirement postmenopausal woman subject surgically sterilize otherwise proven sterile . Male subject partner woman childbearing potential abstinent undergone successful vasectomy must use , partner must use , highly effective method contraception commence least one menstrual cycle prior start study drug , throughout entire study period 90 day study drug discontinuation . Are willing able comply aspect protocol . Exclusion : A family history , past medical history clinical sign symptom bleed diathesis History medical condition result increase risk bleed include limited active recurrent gastric ulcer , recent head trauma surgery , severe hypertension , bacterial endocarditis etc Subjects history spontaneous gum bleed clinical sign symptom physical exam Clinically significant ocular disease untreated visual ocular symptom Clinically significant abnormal electrocardiogram ECGs prior dose ( Screening Baselines ) include QT interval correct heart rate use Fredericia 's formula ( QTcF ) and/or Bazett 's formula ( QTcB ) great 450 m Any history past medical condition result QTc prolongation tachyarrhythmia Torsades de Points ( include hypokalemia , know family history long QT syndrome , know risk factor Torsades de Points ) A platelet count le 150,000 great 390,000 per mL Screening Baseline Period 1 Abnormal ( less 80 % ) arachidonic acid induce platelet aggregation Baseline Period 1 History unexplained syncope , hepatobliary disease , sinus bradycardia , heart block , sicksinus syndrome , cardiogenic shock , heart failure , seizure , chronic obstructive lung disease Subjects hypotension ( le 90 mm Hg systolic ) bradycardia ( HR le 40 beat per minute ) symptomatic bradycardia ( HR le 50 beat per minute ) Received blood , donate blood , experience significant blood loss within 60 day prior checkin Hypersensitivity diltiazem related compound ingredient formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>